Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.
Clinical trial NCT00263679 · COMPLETED
Trial details
- NCT number
- NCT00263679
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2003-11-01
- Primary completion
- 2004-05-01
- Enrollment
- 321
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.